Endometrial Cancer Market Overview:
The global endometrial cancer market size is
USD 22187.69 million expecting a robust CAGR 4.20% and a strong market presence
during the forecast period 2022-2030 in an
all-inclusive study asserts Market Research Future (MRFR). Endometrial
cancer is also known as uterine cancer and is the sixth most common cancer in
women across the world. The daunting number speaks for itself and promotes the
factors that ensure the market growth for endometrial
cancer.
Market Dashboard:
The market is witnessing significant funding
going into research and developments. For instance, Salk Institutes is getting
a sizeable amount of fund from Padres Pedal the Cause. Others are mainly
focusing on mergers and acquisitions. Royal Philips acquiring EPD Solutions can
be taken exemplary. Boston Scientific has also acquired EMcision, Ltd.
Global endometrial
cancer market players are Pfizer Inc., General Electric Company,
Koninklijke Philips N.V., LUPIN, PHYTON, Bayer AG, Celgene Corporation, Johnson
& Johnson, CooperSurgical Inc., LiNA
Medical USA, Conceptus Inc., Hologic Inc., Karl Storz GmbH & Co. Kg, and
Boston Scientific Corporation.
Drivers and Restraints:
Urbanization across the world is experiencing
an express speed growth rate owing to which the population is undergoing
remarkable lifestyle change. A sedentary
lifestyle has become the norm for many, and
growing obesity among women is resulting
in the rising number of endometrial
cancer. Lack of nutritional elements in consumed food and other diseases such
as polycystic ovarian syndrome (PCOS) and the ovarian
tumor can trigger endometrial cancer.
However, a few factors are currently acting as
market irritants such as high diagnostic
cost, expensive treatment, and
side-effects associated with the procedure.
Coupled with these factors, stringent government policies regarding the treatment can also create a bottleneck
situation for the market.
Industry Trends:
According to the Journal of Clinical Oncology,
researchers of John Hopkins Medicine have found a new way to treat uterine cancer by adding the drug trastuzumab to
the chemotherapy regimen of the uterine cancer patients. The drug prolongs the
tumor growth process and gives the physicians a better
opportunity to cure the patients.
A new finding by the researchers in Huntsman
Cancer Institute (HCI) at the University of Utah reveals that in many uterine
cancer tissues steroid and hormone receptors are acting simultaneously causing an escalation in the growth of the tumor.
PapSEEK is a type of liquid biopsy which is
now enabling researchers to identify endometrial cancer at a very early stage.
The screening procedure is still in its early
stage, but it can surely benefit the
doctors in diagnosing and treating their patients.
Segmentation:
The global endometrial cancer
market can be segmented by diagnosis, treatment, and end-user.
By diagnosis, the market can further be segmented into the pelvic examination, transvaginal ultrasound, endometrial biopsy,
dilation and curettage (D&C), and laparoscopy. Endometrial biopsy is very common as the confirmatory test for uterine cancer.
Treatment-based market includes hysterectomy techniques,
radiation, hormone therapy, chemotherapy, and palliative care. The hysterectomy
techniques category comprises open abdominal hysterectomy, total vaginal
hysterectomy, total laparoscopic hysterectomy, and robotic hysterectomy.
External radiation and internal radiation (brachytherapy) are part of radiation
technology. The hormonal therapy consists
progestins, tamoxifen, luteinizing hormone-releasing hormone agonists, and
aromatase inhibitors. Chemotherapy can be further sub-segmented into
paclitaxel, carboplatin, doxorubicin, and cisplatin and is also the most-used
treatment method.
Based on the end-users the market can be
segmented into hospitals and clinics, ambulatory surgical centers, diagnostic
centers, gynecology centers, feminist health centers, and others.
Regional Analysis:
Region-wise the global endometrial
cancer market insights covers the Americas, Europe, Asia-Pacific (APAC),
and the Middle East and Africa (MEA).
The Americas are currently holding the largest market share and can continue to do so in the near future. The region is experiencing a
growing number of endometrial patients
who are spending much on diagnostic and treatment. The region has a well-structured healthcare system and extensive research units who are also
contributing significantly to the regional market.
Europe is currently holding the second
position in the market. Robust healthcare sector and advanced technologies are
supporting the European market for uterine cancer treatment.
The APAC can also witness significant growth in the market owing to rising
incidence of cervical cancer in countries such as India and China.
About US:
Market Research Future (MRFR), enable
customers to unravel the complexity of various industries through Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
Contact us:
Market Research Future (part of Wantstats
Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
United States of America
No comments:
Post a Comment